NITROGLYCERIN tablet United States - English - NLM (National Library of Medicine)

nitroglycerin tablet

bryant ranch prepack - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin sublingual tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). nitr

NITROGLYCERIN tablet United States - English - NLM (National Library of Medicine)

nitroglycerin tablet

bryant ranch prepack - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin sublingual tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). nitr

NITROGLYCERIN tablet United States - English - NLM (National Library of Medicine)

nitroglycerin tablet

natco pharma usa llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin sublingual tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury

NITROGLYCERIN tablet United States - English - NLM (National Library of Medicine)

nitroglycerin tablet

medical purchasing solutions, ll - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin sublingual tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hem

NITROGLYCERIN TRANSDERMAL SYSTEM patch, extended release United States - English - NLM (National Library of Medicine)

nitroglycerin transdermal system patch, extended release

zydus pharmaceuticals usa inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.2 mg in 1 h - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

NITROGLYCERIN TRANSDERMAL SYSTEM- nitroglycerin patch
NITROGLYCERIN TRANSDERMAL SYSTEM- nitroglycerin patch United States - English - NLM (National Library of Medicine)

nitroglycerin transdermal system- nitroglycerin patch nitroglycerin transdermal system- nitroglycerin patch

major pharmaceuticals - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.2 mg in 1 h - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

NITROGLYCERIN aerosol, metered United States - English - NLM (National Library of Medicine)

nitroglycerin aerosol, metered

rouses point pharm - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug - nitroglycerin lingual aerosol is indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. administration of nitroglycerin lingual aerosol is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cgmp)-specific phosphodiesterase type 5 (pde5), as pde5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. do not use nitroglycerin lingual aerosol in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. [see drug interactions (7.1) ]. nitroglycerin lingual aerosol is contraindicated in patients with severe anemia. nitroglycerin lingual aerosol is contraindicated in patients with increased intracranial pressure nitroglycerin lingual aerosol is contraindicated in patients who have shown hypersensitivity to it or to other nitrates or nitrites. skin reactions consistent with

NITROGLYCERIN film, extended release United States - English - NLM (National Library of Medicine)

nitroglycerin film, extended release

kremers urban pharmaceuticals inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 20.8 mg - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.

NITROGLYCERIN ER- nitroglycerin capsule United States - English - NLM (National Library of Medicine)

nitroglycerin er- nitroglycerin capsule

avkare - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 2.5 mg - nitroglycerin extended-release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of oral nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it.

NITROGLYCERIN TRANSDERMAL DELIVERY SYSTEM- nitroglycerin patch United States - English - NLM (National Library of Medicine)

nitroglycerin transdermal delivery system- nitroglycerin patch

physicians total care, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 2.5 mg in 1 d - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.